Temporal trends in utilization of transcatheter aortic valve replacement and patient characteristics: A nationwide study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 932 KB, PDF-dokument
Aim: To investigate trends in the utilization of transcatheter aortic valve replacement (TAVR) and changes in the characteristics of patients undergoing first-time TAVR. Methods: Using Danish nationwide registers, we included all patients undergoing TAVR between 2008 and 2020. To compare patient characteristics, the study population was stratified according to calendar year of procedure: 2008-2010, 2011-2013, 2014-2016, and 2017-2020. Results: We identified 6,097 patients undergoing TAVR with year-by-year increases in TAVR penetration rate. Over time, the age of the patients remained stable (2008-2010: median age 82 year [interquartile range (IQR): 77-86] vs 2017-2020: median age 81 years [IQR: 77-85]). Moreover, there was an increase in male patients (2008-2010: 49.9% vs 2017-2020: 57.4%) and patients with diabetes (2008-2010: 14.2% vs 2017-2020: 19.2%). Conversely, a history of stroke (2008-2010: 15.8% vs 2017-2020: 13.1%), previous myocardial infarction (2008-2010: 22.4% vs 2017-2020: 10.0%), heart failure (2008-2010: 40.5% vs 2017-2020: 25.2%), and peripheral artery disease (2008-2010: 14.8% vs 2017-2020: 10.4) decreased among patients. Conclusions: TAVR utilization increased markedly in the years 2008-2020. Patients undergoing TAVR had less comorbidity over time while age remained stable. Thus, despite expanding to patients at lower surgical risk, TAVR is still offered mainly to older patients.
Originalsprog | Engelsk |
---|---|
Tidsskrift | American Heart Journal |
Vol/bind | 243 |
Sider (fra-til) | 140-146 |
Antal sider | 7 |
ISSN | 0002-8703 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
CTP: Grants from Bayer and Novo Nordisk not related to current study. ELF: Independent research grant from Novo Nordisk Foundation. LK: Speakers honorarium from Novartis, Novo, Boehringer and AstraZeneca. LS: Consultant fees and/or institutional research grants from Abbott, Boston Scientific, Edwards Lifesciences, Medtronic, SMT and Symetis. JBO: Speaker honoraria or consultancy fees from Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Novartis Healthcare, and Novo Nordisk. The other authors declare that they have no conflicts of interest relevant to the content of this manuscript.
Publisher Copyright:
© 2021
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
ID: 290110493